Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:
(a) whether it is true that the share of Public Sector Undertakings (PSUs) in Universal Immunization Programme (UIP) had been miniscule or nil during the last three years;
(b) if so, the details thereof and the reasons therefor; and
(c) the fresh steps taken by the Government to boost home production of vaccines by the PSUs to ensure uninterrupted supply of vaccines for UIP as well as to ensure health security of the country?
(a) to (b) No, madam. The Government is not exclusively dependent on the private sector for the vaccines produced by Public Sector Undertakings (PSUs). However, substantial requirement of remaining vaccines under Universal Immunization Programme (UIP) is being met through the private sector. The status of production & supply of the vaccine manufactured by the Public Sector Vaccine Manufacturing Institutes during the last three years is as under:
Name of Product 2014-15 2015-16 2016-17
Production Supply Production Supply Production Supply
DPT (Lakh Doses) 64.91 17.52 52.86 66.00 -- 34.09
TT (Lakh Doses) 46.68 34.50 76.98 42.00 64.71 76.00
(c): The Government has approved projects of the following Public Sector Vaccine Manufacturing Units for up-gradation with increase in annual installed capacity:
(i) Central Research Institute (CRI), Kasauli;
(ii) BCG VL, Guindy; and
(iii) Pasteur Institute of India (PII), Coonoor.
CRI, Kasauli has already started functioning after up-gradation. BCG VL Guindy has also produced the consistency batches of BCG Vaccine and its quality testing is underway. After clearing the testing protocols, BCG VL, Guindy will supply 45-50 lakh doses of BCG Vaccines per month from August, 2018 onwards. The up-gradation project of PII, Coonoor is nearing completion and the production of trial batches will commence by August, 2018.
In addition, the Government has also approved establishment of Project of National Importance, namely Integrated Vaccine Complex (IVC) as a subsidiary of HLL Life Care Ltd. with a cost of Rs.594 Crores. On completion of the project, IVC would produce Pentavalent Vaccine BCG, Measles, Hepatitis B Human Rabies and Japanese Encephalitis Vaccines. As per policy decision, CRI, Kasauli and PII, Coonoor will supply 75% of Bulk Production of DPT components to IVC for production of Pentavalent Vaccine. After utilization of full capacity of the Public Sector Vaccine Manufacturing Institutes, the dependency on private manufacturing units will be reduced considerably.
*****